CAPR9:00 AMCapricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society CongressPresentation / Abstract • Phase 3WMS late-breaking poster presentation Mon, Oct 5, 2026, 9:00 AM EDTGcapricor.com
CAPR8:30 AMCapricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society CongressPresentation / Abstract • Phase 3WMS late-breaking poster session Tue, Sep 29, 2026, 8:30 AM EDTGcapricor.com
CAPR9:25 AMCapricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLAcapricor.com
CAPR4:05 PMCapricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updatecapricor.com
CAPR8:30 AMCapricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13capricor.com
CAPR9:30 AMCapricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocelcapricor.com
CAPR10:05 AMThe Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular DystrophyTrial Results • Phase 3Results event Wed, Jul 29, 2026, 10:05 AM EDTGcapricor.com
CAPR11:00 AMCapricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocelcapricor.com